↓ Skip to main content

Understanding the benefit of metformin use in cancer treatment

Overview of attention for article published in BMC Medicine, April 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

9 tweeters
1 patent
1 Facebook page


221 Dimensions

Readers on

219 Mendeley
3 CiteULike
1 Connotea
Understanding the benefit of metformin use in cancer treatment
Published in
BMC Medicine, April 2011
DOI 10.1186/1741-7015-9-33
Pubmed ID

Ryan JO Dowling, Pamela J Goodwin, Vuk Stambolic


Biguanides have been developed for the treatment of hyperglycemia and type 2 diabetes. Recently, metformin, the most widely prescribed biguanide, has emerged as a potential anticancer agent. Epidemiological, preclinical and clinical evidence supports the use of metformin as a cancer therapeutic. The ability of metformin to lower circulating insulin may be particularly important for the treatment of cancers known to be associated with hyperinsulinemia, such as those of the breast and colon. Moreover, metformin may exhibit direct inhibitory effects on cancer cells by inhibiting mammalian target of rapamycin (mTOR) signaling and protein synthesis. The evidence supporting a role for metformin in cancer therapy and its potential molecular mechanisms of action are discussed.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 219 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 3 1%
South Africa 2 <1%
United Kingdom 2 <1%
Sweden 1 <1%
Australia 1 <1%
Chile 1 <1%
Italy 1 <1%
Lithuania 1 <1%
Netherlands 1 <1%
Other 4 2%
Unknown 202 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 42 19%
Researcher 33 15%
Student > Bachelor 28 13%
Student > Postgraduate 24 11%
Student > Ph. D. Student 24 11%
Other 57 26%
Unknown 11 5%
Readers by discipline Count As %
Medicine and Dentistry 75 34%
Agricultural and Biological Sciences 59 27%
Biochemistry, Genetics and Molecular Biology 23 11%
Chemistry 14 6%
Pharmacology, Toxicology and Pharmaceutical Science 10 5%
Other 20 9%
Unknown 18 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2019.
All research outputs
of 13,477,526 outputs
Outputs from BMC Medicine
of 2,140 outputs
Outputs of similar age
of 86,626 outputs
Outputs of similar age from BMC Medicine
of 1 outputs
Altmetric has tracked 13,477,526 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.9. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 86,626 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them